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ABSTRACT 
STIMULANT USE, ASSOCIATED PSYCHOPATHOLOGY, AND 
EATING DISORDERED SYMPTOMATOLOGY 
by Tiffany Ann Hopkins 
December 2013 
The current study developed profiles of eating disorder, personality, and other 
psychopathological symptoms related to the use of central nervous system stimulants 
versus other types of drug use. Participants included 124 women in residential treatment 
for substance use with and without comorbid eating disorders. Symptomatology was 
measured by the Eating Disorders lnventory-3 (EDI-3), Millon Multiaxial Inventory-III 
(MCMI-111), and Personality Assessment Inventory (PAl). The current study utilized a 
series of six multivariate analyses of variance (MANOVAs) and discriminant analyses to 
determine patterns of psychopathology separating stimulant use from other drug use. 
Results indicated that women who used stimulants were primarily separated from women 
who used other drugs by scales measuring borderline personality pathology, and to a 
lesser extent, antisocial personality pathology. Stimulant users were also separated from 
other drug users by scales measuring diagnostic or associated features of borderline 
personality disorder (e.g., emotion dysregulation, suicide ideation, paranoia, aggression, 
drug use, and thought disturbance) and mood disturbance. Finally, stimulant users were 
differentiated from other drug users by a scale measuring extreme dieting and longing for 
thinness. Implications for treatment and future research are discussed. 
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CHAPTER I 
INTRODUCTION 
1 
Stimulant use is increasingly prevalent in recent decades. Women now equal men 
in stimulant use and demonstrate unique susceptibility to stimulant addiction due to 
hormonal interactions with stimulants (Greenfield, Back, Lawson, & Brady, 2010). The 
use of stimulants is of particular concern for those with eating disordered symptoms, as 
stimulant use is associated with decreased appetite, improved mood, and weight loss 
(National Center of Addiction and Substance Abuse (CASA) at Columbia University, 
2003). Comorbidity between substance use disorders and eating disorders is associated 
with greater psychopathology and poorer prognosis than the individual diagnosis of either 
disorder (see review: Pearlstein, 2002). The current study assessed differences in 
personality, psychopathology, and eating disordered symptoms associated with the use of 
stimulants versus other types of drugs. 
The background for the present study will be established by first reviewing the 
literature relating substance use disorders to eating disorders, then the literature linking 
substance use disorders to other forms of psychopathology, then the literature relating 
eating disorders to other forms of psychopathology. The integration of these three lines of 
research provide the basis for the present work. The current study addresses a void in the 
literature by examining clinical presentation based on type of substance use. Differences 
in clinical presentation will highlight the need to establish specific treatment modalities 
based on substance type, eating disorder symptomatology, and associated 
psychopathology. 
2 
Substance Use Disorders and Eating Disorders 
Substance use disorders encompass both substance dependence and substance 
abuse. The Diagnostic and Statistical Manual (DSM-IV-TR; American Psychiatric 
Association (APA), 2000) defines the central elements of substance dependence as "a 
cluster of cognitive, behavioral, and physiological symptoms indicating that the 
individual continues use of the substance despite significant substance-related problems" 
(AP A, 2000, p. 192). Individuals with substance dependence often manifest tolerance and 
withdrawal symptoms, desire to decrease substance use, and persist using the substance 
regardless of the negative physical and psychological effects 'caused by the substance. 
Substance abuse is described in the DSM-IV-TR as "a maladaptive pattern of substance 
use manifested by recurrent and significant adverse consequences related to the repeated 
use of substances" (AP A, 2000, p. 198). Specifically, consequences may include 
difficulty fulfilling major role obligations, interpersonal issues, bodily harm, and legal 
ramifications. 
Substance use disorders are categorized on the basis of substance type (AP A, 
2000). Central nervous system stimulants (hereafter: stimulants) include such drugs as 
nicotine, caffeine, methylphenidate (e.g. Ritalin), amphetamines (e.g., Adderall), 
methamphetamines (e.g. speed), and cocaine. Stimulants act on the mesocorticolimbic 
pathway of the brain, also known as the reward pathway, by increasing dopamine levels 
in the nucleus accumbens (Badiani,Belin, Epstein, Calu, & Shaham, 2011). Stimulant 
use is associated with a number of physiological responses, such as diminished appetite, 
hyper-alertness, improved concentration, and elevated mood; in greater amounts, it can 
result in such symptoms as rapid heart rate and breathing, sweating, tremor, and high 
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blood pressure (National Center of Addiction and Substance Abuse (CASA) at Columbia 
University, 2003; Weaver & Schnoll, 1999). Additionally, large, acute doses of 
amphetamine have been linked to aggression and transient psychotic symptoms, 
including paranoia, delusions, and hallucinations; the chronic use of amphetamines may 
result in persistent symptoms of psychosis and paranoia (reviews: Dawe, Davis, 
Lapworth, & McKetin, 2009; Shoptaw, Kao, & Ling, 2009). 
The DSM-IV-TR (APA, 2000) outlines three eating disorder types and two eating 
disorder subtypes. Anorexia nervosa (AN) is diagnosed when "the individual refuses to 
maintain a minimally normal body weight, is intensely afraid of gaining weight, and 
exhibits a significant disturbance in the perception of the shape or size of his or her body" 
(APA, 2000, p. 583). Furthermore, the AN diagnosis can be subtyped into a restricting 
type (ANr) if the focus is on fasting and dieting, and a binge-eating and purging subtype 
(ANbp) when there is a cycle ofbinge-eating and purging (e.g., vomiting, laxative 
misuse). Criteria of bulimia nervosa (BN) include "binge eating and inappropriate 
compensatory methods to prevent weight gain" and "self-evaluation [which is] unduly 
influenced by body shape and weight" (APA, 2000, p. 589). Finally, EDNOS captures a 
wide variety of disordered eating, including binge-eating without purging (i.e., binge 
eating disorder) and subclinical AN or BN (APA, 2000, p. 594). Several studies 
examined associations between specific eating disorder types/behaviors and substance 
use. 
Stimulant use and eating disorder symptomatology have numerous overlapping 
consequences, which may be more severe when the disorders occur comorbidly. 
Specifically, these two disorders consistently demonstrate some of the highest mortality 
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rates associated with psychological disorders (Arendt, Munk-J0rgensen, Sher, & Jensen, 
2011 ; Crow et al., 2009), with the substance use-eating disorder comorbidity resulting in 
higher mortality rates than any other psychiatric comorbidity. Mortality is particularly 
related to substance misuse or overdose and suicide (Franko et al., 2005; Rosling, Sparen, 
Norring, & von Knorring, 2011). Additionally, both substance use and eating disorder 
symptomatology are associated with harmful and often irreversible health effects (Harrop 
& Marlatt, 2010; Greenfield, Gordon, Cohen & Trucco, 2010; Sansone & Sansone, 
1994), pre- and posttreament impairments in quality oflife (Hay & Mond, 2005, Tracy et 
al., 2012), increased social costs (e.g., treatment, job productivity) relative to normative 
populations (Meara & Frank, 2005), and increased health-related economic burden 
(Mitchell et al., 2009; Simon, Schmidt, & Pilling (2005). Additionally, there is an 
indication that those with particular combinations of comorbid diagnoses may have better 
outcomes associated with specific types of treatments. For example, Franko et al. (2005) 
found that recovery of alcohol use disorder with comorbid AN was best predicted by 
group therapy and hospitalization, whereas recovery from comorbid alcohol use disorder 
and BN was best predicted by individual therapy and exercise. Thus, an examination of 
these patterns of comorbidities may result in improved treatment outcomes and 
diminished consequences. 
The literature is replete with studies examining the individual relationship 
between substance use disorders and eating disorders. Wiederman and Pryor (1996) 
described prevalence rates for substance use in the eating disorder population as ranging 
from 17% to 46% depending on the type and subtype of eating disorder. In a review of 
the literature, Holderness, Brooks-Gunn, and Warren (1994) found that of those 
diagnosed with BN, up to 48.6% of individuals were also diagnosed with alcohol abuse 
or dependence, and up to 55% were diagnosed with any drug abuse or dependence. 
Similarly, across studies, they found that of individuals diagnosed with AN restricting 
type, up to 34% were diagnosed with alcohol abuse or dependence and up to 19% used 
illegal drugs. Finally, they reported that of individuals who were diagnosed with a 
combination of anorexic and bulimic symptoms, up to 45% also were diagnosed with 
alcohol abuse or dependence and up to 40% reported using street drugs. There is a clear 
and substantial relationship between substance use disorders and eating disorders. 
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Although individuals with eating disorders may use a wide range of substances, 
there appears to be a unique relationship between stimulant use and eating disordered 
symptomatology. The National Center of Addiction and Substance Abuse (CASA) at 
Columbia University (2003) found that smoking and eating disorder symptomatology 
were closely linked, in that nicotine suppresses appetite and provides an oral replacement 
to eating. They stated that women who smoke reference potential weight gain as a 
motivator for continued use; weight-linked motivation is cited by women at double the 
rate of men. Likewise, they found that women were more liable to resume smoking after 
quitting due to weight gain. Finally, in a study of college students, 39% of women and 
25% of men initiated smoking as a tactic for dieting success (Office of the Surgeon 
General, 2001 ). 
In a study of cocaine abusers, Cochrane, Malcolm, and Brewerton (1998) found 
that almost half of women presenting for cocaine abuse specifically used cocaine as a 
weight control measure; 72% of these were identified as meeting criteria for an eating 
disorder. Similarly, Jonas, Gold, Sweeney, and Pottash (1987) diagnosed eating disorders 
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in one-third of a sample of callers to the National Cocaine Hotline, via a structured 
clinical interview. In addition to appetite suppression, feelings of power and control 
initiated by cocaine have been identified as a motivator for use by women with eating 
disorders (National Center of Addiction and Substance Abuse (CASA) at Columbia 
University, 2003). Parks, Saewyc, Cox and MacKay (2008) found associations with 
stimulant use (i.e., amphetamines, cocaine, or cigarettes), disordered eating, and body 
dissatisfaction in the general population. In a sample of 30,000 British Columbian 
students, they found that individuals who had poor body image, hinged, purged, or dieted, 
had a significantly higher likelihood of using stimulants than those who did not. Purgers 
were four times more likely to use stimulants than non-purgers; bingers, dieters, and 
those dissatisfied with their body were approximately twice as likely to use stimulants 
than their counterparts. 
The stimulants methylphenidate and dextroamphetamine, both of which are used 
to treat Attention Deficit and Hyperactivity Disorder (ADHD), are also utilized for 
nonmedical purposes by individuals seeking weight loss. Williams, Goodale, Shay-
Fiddler, Gloster, and Chang (2004) analyzed the misuse of these substances in 450 
adolescents referred for treatment. They found that having an eating disorder and not 
attending school were the only two predictors which discriminated between stimulant use 
and other drug use; however, the effect size was small (R2 = .075). Dukarm (2005) 
examined six individuals with bulimia nervosa and comborbid ADHD who were 
administered dextroamphetamine as a treatment for both. Patients self-reported a 
complete lack ofbingeing and purging behaviors while on the drug. However, it was 
unclear as to whether the prescribed stimulant was truly alleviating the eating disorder 
symptomatology, or if it was enabling more severe caloric restriction and thus 
extinguishing the binge-purge cycle. 
Neurologically, Vicentic and Jones (2007) have tied cocaine- and amphetamine-
regulated transcript peptides to both food and drug related rewards, which provide 
additional evidence to the link between stimulants and eating disorders. CART peptides 
regulate the mesolimbic dopamine system, which is associated with feeding and 
addiction. Although the temporal precedence of eating disorder symptomology and 
stimulant use has yet to be thoroughly investigated, the literature suggests that stimulant 
use may serve a particular purpose or function (e.g., appetite suppression) among 
individuals with body dissatisfaction or eating disordered symptomatology. 
Specific eating disorder symptoms (e.g., restriction, bingeing, purging) 
demonstrate unique relationships to different types of substance use. Bulik et al. (1992) 
found that individuals with BN or ANbp had significantly higher use of cigarettes (Odds 
Ratio (OR)= 6.33), alcohol (OR= 6.61), laxatives (OR= 7.15), amphetamines (OR= 
5.38), cocaine (OR= 7.03), and marijuana (OR= 4.54), relative to those with ANr. 
Purging, via laxative use, was associated with significantly higher use of emetics, 
marijuana, and amphetamines, when compared to non-laxative users. Wiederman and 
Pryor (1996) associated amphetamine use with increased caloric constraint; the study 
does not make causal claims; however, it may be that stimulant use enabled greater 
constraint. Purging was associated with cocaine, cigarette, and poly-drug use. 
Additionally, purgers were three and a halftimes more likely to use amphetamines and 
cocaine, and four times more likely to smoke, compared to non-purgers (Parkes, Saewyc, 
Cox, & MacKay, 2008). Finally, Piran and Robinson (2006, 2011) found that dieting and 
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purging were associated with the use of stimulants and abuse of sleeping medication, in 
two community samples. Given effect sizes, caloric constraint and purging, 
independently ofbingeing, have a clear and strong relationship to stimulant use. These 
two eating disordered behaviors will be used to explore possible patterns of comorbidity 
associated with stimulant use. 
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Bingeing behaviors, unlike caloric constraint and purging, were generally 
associated with tranquilizer use, hallucinogens (Wiederman & Pryor, 1996), and alcohol 
use (Piran & Robinson, 2006; Wiederman & Pryor, 1996). Pure restriction was generally 
associated with less drug, alcohol, and psychotropic abuse or dependence than restriction 
with binge-eating and purging, or bingeing and purging alone (Corcos et al., 2001; Stock, 
Goldberg, Corbett, & Katzman, 2002). Therefore, purging and caloric constraint appear 
to be uniquely associated with stimulant use. 
Substance Use and Associated Psychopathology 
Historically, men were identified as having higher rates of substance use than 
women; however, recent clinical studies note a change in this trend. In a review of 
epidemiological surveys on substance abuse, Greenfield et al. (20 1 0) reported that men 
continue to use cannabis, alcohol, heroin, and nicotine at higher rates than women. 
However, differences between genders have increasingly lessened over time. They noted 
similar rates of stimulant use between genders and evidence of equal or higher rates of 
nonmedical opioid use in women. The use of stimulants by women appears to be 
increasing more rapidly than other types of substances. This increase in stimulant use in 
women is evinced by tripled admission rates in federally funded treatment centers for 
pregnant women between 1994 and 2006, compared to doubled admissions for stimulant 
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treatment in the general population between 1995 and 2005. They also found associations 
between substance use and several psychological disorders (e.g. mood, anxiety, and 
eating disorders), with women who use substances having significantly more psychiatric 
diagnoses than men. These findings suggest that stimulant use is a growing problem 
among women and that patterns of comorbidity associated with stimulant use warrant 
further investigation. 
Chen et al. (20 11) examined psychiatric comorbidities associated with specific 
types of substance use by gender in an inpatient treatment sample (N = 465). In females, 
the most common comorbidity was cocaine dependence and "any other psychiatric 
disorder" (Male/Female odds-ratio= .54). Of women who used cocaine, comorbid 
diagnoses were mood disorders (32.6% ), anxiety disorders (31 .1% ), psychotic symptoms 
( 13.1% ), Borderline Personality Disorder (27. 7% ), and Antisocial Personality Disorder 
(12.2%). These psychiatric comorbidity rates were greater than with any other type of 
drug. 
Stimulant use was also associated with depression. Bohnert and Miech (20 1 0) 
reported increases in the association between cocaine use and depressive disorders 
between the 1980's (Odds Ratio (OR)= 1.28) and 1990's (OR= 3.53). Of treatment-
seeking cocaine users, depression was noted as one of the most frequent co-occurring 
psychological disorders (Kleinman et al., 1990; Rounsaville et al., 1991 ); further, many 
treatment-seeking users suffered from subclinical levels of depressive symptomatology. 
Additionally, depressed cocaine users reported greater euphoria associated with cocaine 
administration than nondepressed users, suggesting that cocaine use may be motivated or 
maintained by a desire to alleviate negative emotions (Newton, Kalechstein, Tervo, & 
Ling, 2003; Uslaner, Kalechstein, Richter, Ling, & Newton, 1999). 
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Levental et al. (2010) reported that anhedonia, defined as diminished interest and 
pleasure in rewarding activities, had a particular relationship to stimulant use in a cross-
sectional, population based sample (N = 43,093). Specifically, they found a distinct 
relationship between stimulant use or dependence with anhedonia and depressed mood 
across stimulant types (e.g. amphetamine, cocaine). Further, the relationship remained 
significant after controlling for demographic, psychiatric, and non-stimulant substance 
use characteristics. Odds ratio effect sizes were relatively large, as those using 
amphetamines were 3.31 times more likely to exhibit anhedonia, whereas those using 
cocaine were 2.56 times more likely to exhibit anhedonia. The effects were partially 
attenuated with the introduction of controls; however, they remained in the medium to 
high range. 
Although these studies demonstrate an association between stimulant use and 
depression, there is a dearth of literature comparing depression severity among specific 
types of substance use disorders, with only one study directly comparing psychological 
comorbidities among different typologies of substances. Nevertheless, this literature 
suggests that stimulant users may display elevated rates of depression relative to other 
drug users. 
Marken et al. (1992) found that marijuana and stimulants were the most 
commonly used illicit substances taken by inpatient individuals with manic symptoms. 
Similarly, Winokur et al. (1998) found that alcohol and stimulant abuse rates were 
significantly higher among bipolar groups than in unipolar or control groups. Stimulant 
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use is also being investigated as a potential treatment for bipolar disorder (Pagano, 
Demeter, Faber, Calabrese, & Findling, 2008; Wingo & Ghaemi, 2008). It is possible that 
those presenting with stimulant use may have elevations on scales measuring mania, 
though they may not actually present with bipolar disorder. Stimulant use and mania are 
associated with similar symptoms (e.g. decreased need for sleep, racing thoughts), and 
measures may not be able to differentiate between the two disorders. 
Stimulant users also demonstrate elevations in anxiety sensitivity and anxiety 
disorders. Buckner, Proctor, Reynolds, Kopetz, and Lejuez (2011) found that anxiety 
sensitivity had a significant association to cocaine dependence; the relationship remained 
significant even when controlling for sex, age, alcohol dependence, hallucinogen 
dependence, major depressive disorder, panic disorder, and posttraumatic stress disorder. 
Herrero, Domingo-Salvany, Torrens, Brugal, & I.T.I.N.E.R.E. (2008) found that anxiety 
disorders were the second most common comorbidity (13%) among cocaine-users, 
surpassed only by mood disorders (26.6%; see also: Chen et al., 2011). Although there is 
a scarcity of research regarding the association between specific types of anxiety 
disorders and stimulant use, as well as the role of other types of substances, the literature 
indicates that stimulant users may have elevations in general measures of anxiety, relative 
to other types of drug users. 
In a review of stimulant use and psychosis, Curran, Byrappa, and McBride (2004) 
found evjdence for brief psychotic states brought on by large doses of stimulant drugs, 
which resolved within a few hours. They additionally found that the presence of positive 
symptoms of psychosis prior to stimulant use resulted in increased symptom severity 
upon initiation of stimulant use. However, the review noted two studies in which the 
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chronic use of injectable stimulants resulted in increased rates of chronic psychosis, with 
continued symptomatology long after stimulant use was discontinued (see also: Dawe et 
al., 2009; Shoptaw et al., 2009). Subsequent studies reported that 'chronic' or persistent 
psychosis among stimulant users was predicted by the early onset of stimulant use and 
extended duration of use (Chen et al. 2003; Lichlyter, Purdon, & Tibbo, 2011). 
Certain personality traits may be conceptualized as risk factors for substance use 
disorders. Grekin, Sher, and Wood (2006) found that specific personality patterns were 
predictive of certain types of substance misuse. Namely, antisociality, novelty seeking, 
conduct disorder symptoms, and neuroticism were predictive of a variety of substance 
misuse. They additionally found unique personality patterns associated with alcohol, 
nicotine, and general drug use. For example, alcohol use symptoms were predicted by 
high extraversion and low openness, drug symptoms were predicted by low 
conscientiousness, and tobacco symptoms were predicted by high openness and low 
conscientiousness. Similarly, Kotov, Gamez, Schmidt, and Watson (2010) found that of 
the 'Big Five' personality traits, only disinhibition was associated with substance use. A 
high level of novelty seeking was associated with significantly greater stimulant use, with 
stimulant users being motivated by obtaining positive rewards (Adams et al., 2003). In a 
review of neuroimaging studies of stimulant users, Li and Sinha (2008) noted that 
stimulant use was associated with brain activity suggestive of impairments in cognitive 
inhibition and emotion regulation, as well as in increased impulsivity. In a review 
comparing stimulant and opioid addiction, Badiani et al. (2011) reported that in multiple 
animal studies, rats who later developed stimulant addictions demonstrated unique 
elevations in trait impulsivity prior to initiation of stimulant use; stimulant use 
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administration resulted in increased expression of impulsivity. The relationship with 
impulsivity was not found in opioid addicted rats. 
Valila (2008) attempted to differentiate personality traits between participants 
who identified CNS stimulants, depressants, or opioids as their drug of choice. He found 
a large effect (Partial Eta Squared = .85) for drug of choice on personality trait scores. 
Specifically, participants who engaged in CNS stimulant use were significantly higher on 
the Extraversion domain, whereas CNS depressant and opioid users were higher on the 
Neuroticism domain than stimulant users. Thus, distinct personality traits are associated 
with specific types of substance use. Stimulant use will likely be associated with 
personality disorders in which reward seeking, extraversion, disinhibition, impulsivity, 
and emotion dysregulation are emphasized. When these personality traits are considered 
in the context of other cognitive and behavioral changes associated with stimulants (e.g., 
transient psychosis, paranoia, & aggression), the overall clinical picture is suggestive of 
borderline personality disorder. 
Stimulant use is associated with specific personality disorders, namely, antisocial 
. . . 
personality disorder and borderline personality disorder. Paim-Kessler et al. (2012) found 
that crack users presented with significantly higher rates of antisocial personality 
disorder, relative to both powder cocaine and other psychoactive substance users. 
Furthermore, Echeburtia, DeMedina, and Aizpiri (2009) compared personality disorders 
among individuals presenting with pure alcohol dependence and comorbid cocaine abuse 
and alcohol dependence. Individuals presenting with comorbid cocaine abuse had 
significantly higher rates of antisocial (21% ), narcissistic (14.5% ), and borderline 
(11.3%) personality disorders, relative to individuals with pure alcohol use. However, 
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borderline personality disorder, followed by other cluster B disorders, were also the most 
common personality disorders in all individuals presenting for substance use treatment 
(Ray, Primack, Chelminski, Young, & Zimmerman, 2011). Furthermore, Feske, Tarter, 
Kirisci, and Pilkonis (2006) found that borderline personality disorder was a significant 
predictor for multiple categories of substance use, including: any substance use disorder, 
alcohol use, drug use, heroin, cocaine, or poly-substance use. Antisocial personality 
disorder emerged as a partial mediator of the relationship between borderline personality 
disorder and substance use disorders. Thus, stimulant use is associated with increased 
rates of antisocial and borderline personality disorders across several studies; only one 
study found an association to narcissistic personality disorder. However, the high rates of 
these personality disorders across substance use types may obscure particular 
relationships. 
The literature suggests that individuals who use stimulants, relative to other types 
of substances, may present with increased prevalence or severity of mood disorders, 
psychotic disorders, and borderline and antisocial personality disorders. Additionally, 
individuals using stimulants may have elevations in core symptoms of anxiety; however, 
the relationship between specific anxiety disorders and substance use disorders remains 
unclear. Of note, the preponderance ofthe research examined the relationships between 
only two individual constructs at a time, which prevents the identification of common 
clusters of disorders and those disorders which may demonstrate greater impact or 
relevance to individuals who use specific types of substances. 
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Eating Disorders and Associated Psychopathology 
Given the strong link between stimulant use and particular eating disorder 
behaviors such as caloric constraint and purging (Parkes et al. , 2008; Piran & Robinson, 
2006 & 2011; Wiederman & Pryor, 1996), it is important to examine psychopathology 
associated with these behaviors, as it may influence the clinical pattern found in stimulant 
users. In a review of the literature, Pearlstein (2002) found that major depression and 
dysthymia were highly prevalent across eating disorder types and subtypes. In a separate 
review, O'Brien and Vincent (2003) found that the highest rates of depression occurred in 
the ANbp subtype; given that this subtype is defined, in part, by caloric constraint and 
purging, depression and stimulant use may be linked through eating disordered 
psychopathology (see also review: Casper, 1998). Purging, alone or with bingeing, was 
consistently linked to increased levels of depression when compared to other types of 
eating disorder behaviors (Garner, Garner, & Rosen, 1993). These findings give added 
support to the hypothesis that stimulant use will result in higher levels of depression than 
other drug use, given the association between stimulant use, purging, and caloric 
constraint. 
In a review of the literature, Pearlstein (2002) reported that eating disorders have 
not generally been linked to bipolar disorder, citing only three studies in the last twenty 
years. In a few instances, elevations in bipolar II were linked specifically to BN; 
similarly, rates of eating disorders were found to be minimally elevated in a bipolar 
sample. Therefore, although stimulant use alone has associations with mania, the 
literature suggests that eating disorder symptomatology may not have a role in these 
findings. 
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Anxiety disorders, specifically obsessive-compulsive disorders and social 
phobias, were commonly associated with eating disorders and substance use disorders. 
Lifetime prevalence rates range from 20-55% in AN and 13-75% in BN (Bulik et al., 
1992; Pearlstein, 2002). Social phobias appeared to occur equally in AN and BN, 
whereas obsessive compulsive disorder occurred more in AN (Pearlstein, 2002). For 
individuals in treatment for substance use disorders with eating disorder symptoms, 
posttraumatic stress disorder (PTSD) symptoms were significantly higher in those who 
reported bingeing (Cohen et al., 2010). Spindler and Milos (2007) found that binge-eating 
and purging behaviors were linked to increased anxiety (Odds Ratio = 1.90 - 2.22) and 
substance use (OR= 1.65 for vomiting, 1.89 for bingeing, and 4.23 for laxative use). 
Similarly, they found that dieting and fixation on being underweight was related 
specifically to anxiety disorders (OR = 4.23); weight and appearance concerns were 
concomitant with affective (OR = 1.81) and anxiety (OR = 2. 77) disorders. Given the 
association of stimulant use with caloric constraint and purging, findings indicate that 
stimulant use may be associated with increased symptoms of anxiety. However, specific 
types of anxiety disorders may not demonstrate a consistent relationship with stimulant 
use. 
The personality trait of obsessionality may serve as a protective mechanism 
against substance use disorders in individuals with eating disorders (Thompson-Brenner 
et al. , 2008). Vitousek and Manke (1994) found that individuals diagnosed with AN were 
often identified as restrained, compliant and obsessional. Those diagnosed with BN were 
less consistent in personality, though affective instability and impulsivity were 
particularly common. In a review, Pearlstein (2002) found the previous associations as 
well as stress reactivity, affective dysregulation, impulsivity, novelty seeking, low self-
esteem and interpersonal sensitivity in those with BN (see also reviews: Lilenfeld et al., 
2000; Wonderlich & Mitchell, 2001); those with AN were further associated with 
perfectionism and negative self-evaluation. 
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Personality disorders were likewise linked to specific eating disordered behaviors, 
which in turn have particular relationships to stimulant use (e.g. caloric constraint, 
purging). Borderline personality disorder was consistently linked to bingeing and purging 
behaviors in AN binge-purge type and BN, at rates ranging from 33% to 71% (O'Brien & 
Vincent, 2003; Pearlstein, 2002; Rosenvinge, Martinussen, & Ostensen, 2000). Similarly, 
Spindler and Milos (2007) found that binge-eating and purging behaviors were linked to 
increased cluster B personality disorders (OR = 2.12- 2.65). 
Rosenvinge et al. (2000) performed a meta-analysis of studies regarding 
personality disorders and eating disorders from 1983 to 1998. They found that cluster C 
personality disorders (i.e. dependent, avoidant, obsessive-compulsive) occurred in equal 
rates across eating disorders, at rates of approximately 45%. Additionally, they found that 
cluster A disorders (i.e. paranoid, schizoid, and schizotypal) had a higher prevalence in 
BN, at 27%, compared to 12% of AN patients. In cluster B disorders (i.e. narcissistic, 
borderline, antisocial, and histrionic), BN (44%) was likewise higher than AN (15%). In 
a review of the literature, Pearlstein (2002) reported that AN was most commonly 
associated with avoidant personality disorder, whereas BN was most commonly 
associated with borderline personality disorder. Additionally, borderline personality 
disorder was specifically associated with the purging subtype of ED NOS (e.g. Purging 
Disorder). 
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A few authors utilized multivariate analysis to examine psychopathology 
associated with specific eating disordered types and behaviors. Craig (1997) examined 
the personality and clinical scales of the MCMI-III in a group of eating disordered 
patients (N = 70). Discriminate analysis determined that the Dysthymia, Major 
Depression, and Thought Disorder scales discriminated the AN and AN binge/purge type 
from the BN and EDNOS groups (SCC = .41). Given that the ANbp subtype is partially 
defined by purging and caloric constraint, the Dysthymia, Major Depression, and 
Thought Disorder scales of the MCMI-III may also demonstrate elevations among 
stimulant users. Ciccolo and Johnsson (2002) identified three clusters of associations with 
eating disordered behaviors. The cluster associated specifically with purging, in isolation 
or with bingeing, had elevated levels of aggression and somatization, as well as lower 
levels of interoceptive awareness. Similarly, Garner et al. (1993) associated purging with 
greater levels of depression, panic disorders, anxiety, and suicide attempts. Given the 
association between purging and stimulant use (Piran & Robinson, 2006; 2011), these 
forms of psychopathology may be similarly elevated among stimulant users. 
The literature suggests the eating disordered symptoms associated with stimulant 
use may be related to increased depression, general anxiety, thought disturbance, and 
borderline personality disorder, compared to eating disorder symptoms associated with 
other types of substances. As the vast majority of studies examined the confluence of two 
disorders at a time, despite the multiple comorbidities associated with stimulant use, the 
relative importance of a given disorder to the overall clinical presentation remains 
unclear. 
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The Present Study 
There is considerable literature demonstrating associations between substance 
use, eating disorders, personality disorders, and other clinical syndromes, but almost 
always relating two groups of disorders at a time (e.g., eating disorders and substance 
use). There is also evidence in the literature that.comorbidities between any pair of 
disorder groups predicts poorer prognosis and that various combinations may respond 
differently to treatment modalities. In treatment settings, patients may present with more 
than two comorbid disorders. For example, it is not uncommon for substance use to be 
comorbid with eating disorders, personality symptoms, depression, and anxiety. Such 
complicated cases can be very difficult to treat and even more challenging in the 
development of a case formulation. Identification of common clusters of co morbidity is a 
logical first step toward clarifying the complex relationships among these multiply 
comorbid cases, which may in turn allow identification of specific intervention strategies 
to more effectively treat specific comorbid combinations. 
The present study examines differences in personality, psychopathology, and 
eating disorder symptomatology between women who use stimulants compared with 
women who use other types of drugs. In the literature, stimulant use has been associated 
with specific types of psychopathology and eating disorder behaviors (Table 1), 
particularly mood disorders, anxiety, psychosis, borderline and antisocial personality 
disorders, caloric constraint, and purging. Similarly, the eating disorder behaviors 
associated with stimulant use are associated with elevations in depression, anxiety, 
thought disturbance, and borderline personality disorder. Therefore, stimulant use is 
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predicted to be associated with higher overall levels of psychopathology and personality 
symptoms; specifically, stimulant users will have significantly higher mood and anxiety 
scores, thought disturbance/psychosis scores, and borderline and antisocial personality 
scores. Additionally, stimulant use is predicted to result in higher eating disorder 
pathology, and thus elevated scores on the EDI-3 risk composites and the associated 
psychological scale (i.e., Emotion Dysregulation). 
Table 1 
Summary of Reported Findings 
Stimulant AN BN BED ANr ANbp ! Restrict Binge Purge 
use 
Stimulants Ill I 111111 I 111111 
Hallucinogen li 
Alcohol II IIIII I II I 
Marijuana I li! II I l 
Sedatives ·~ 
. I 
Tranquilizer I l 
Poly-drug use I 
Depression IIIII II 1111 11 1 111111111111 II II II 111111 Ill 
Mania/ Bipolar 111111 I 
D~sth~mia I I Ill Ill I, I ! Anxiety 1 111 111111 1111 II , I ll 
Social Phobia Jllllllll 111111111 
OCD 1111111111 IIIII 
11111111 
Panic Disorder I I 
PTSD Ill IIIII I I 
Somatization I 
Psychosis/ 111111111111111 I I 
Thought Dist. 
Paranoia I ll 
Borderline !Ill N II I I 
Antisocial Ill 
Other Clust. B I I ! I I i Cluster A I 
Cluster C l I 
Impulsivity 111111111 II I 
Disinhibition 1
111111ll 
I I i I I Emotion D~s. IIIII I Aggression I I Reward I I ~ Seeking I Extraversion II I I I 
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Table 1 (continued). 
I Stimulant AN BN BED ANr ANbp Restrict Binge Purge 
use 
Novelty II II I I II Seeking Suicide I Attempts 
Aggression I I 
Concern with 
I" body/ weight 
Eating I IIIII Disorder 
Thought Dist.: Thought Disturbance 
Other Clust. 8 : Other Cluster B 
Emotion Dys.: Emotion Dysregulation 
I 
~ 
r I 
Note: Individual studies are counted from each review, to prevent under or over examination of relationships 
The current study is particularly valuable, as there is a dearth of literature 
regarding patterns of multiple comorbidity associated with particular types of substance 
use. Relatively few studies have examined differences in presentation based on substance 
use type, with even fewer studies examining these presentations multivariately. If 
expected differences are found, the current study may indicate the need to establish 
specific treatment modalities based on comorbid eating disorder and substance use 
combinations. 
I 
CHAPTER II 
METHODOLOGY 
Subjects 
Subjects were a convenience sample of women at a residential treatment center 
for women with substance use disorders, with and without comorbid eating disorders. 
Although the current sample contained a portion of women with AN, BN, and EDNOS 
diagnoses, all of these women had the central feature of binge eating or purging. There 
were no pure restrictors in this sample. The target population for the current study was 
women who engage in substance use. Although all women were being treated for 
substance use disorders with or without comorbid eating disorders, not all women will 
meet the clinical level for both diagnoses. All data gathered were part of standard 
assessments given upon admission to the treatment facility. Subjects were from various 
locations across the United States, though all obtained treatment in the southeastern 
United States. 
22 
The present study included a mix of approximately 70 archival participants and 
approximately 50 voluntary participants, for a total of 124 female participants. Archival 
data was obtained between December 2009 and October 2012, and was de-identified at 
the treatment facility before being released for research. It was not feasible to contact 
these patients individually; however, permission was granted by two Institutional Review 
Boards (Appendix A) before utilizing data from these patients. All participants entering 
the study from November 2012 to March 2013 gave informed consent for their data to be 
utilized in the study, with the understanding that their participation, or lack thereof, 
would in no way affect their treatment. 
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As effect sizes were consistently large within the literature, effects were expected 
to be large within the current study. Power analysis indicated that with a large effect size, 
92 to 1 06 participants would be sufficient to capture group differences. 
Procedure 
All assessments were given by a mental health clinician, as part of standard intake 
procedures. Furthermore, a certified addictionologist interviewed each patient regarding 
their substance use. A mental health clinician completed a clinical interview to determine 
diagnoses for each participant, using DSM-IV-TR (APA, 2000) criteria. An onsite chart-
review was completed for each participant, within the security parameters of the facility. 
The chart review was utilized to determine diagnoses, frequency, intensity, duration, and 
type of substance use, and to obtain scores from the assessment instruments. Between 
November 2012 and March 2013, all patients were informed that with their consent, their 
data would be used for both research and treatment planning. Upon verbal agreement by 
the patient to participate in the study, the clinician signed and dated the informed consent 
to maintain the patient's privacy. This precaution was utilized as an additional security 
measure, ensuring that there was no possible data trail leading back to the patient' s 
identity. The consent forms and data were stored separately in locked filing cabinets, 
within the security parameters of the institution. 
Instruments 
Three instruments will be utilized in the present study: the Eating Disorder 
Inventory-3 (EDI-3; Garner, 2004), the Personality Assessment Inventory (PAl; Morey, 
1991) and the Millon Clinical Multiaxial Inventory-III (MCMI-111; Millon, Millon, 
Davis, & Grossman, 2009). The EDI-3 will be utilized to determine eating disordered 
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behaviors and associated symptomology, whereas the PAI and MCMI-III will be utilized 
to determine elevations of particular personality disorders and psychopathology (e.g. 
depression and anxiety disorders). 
Eating Disorder Inventory-3 
The EDI-3 is a 91 item self-report instrument which measures psychological and 
behavioral traits common to eating disorders. The instrument is designed to be used as an 
aide to diagnosis, in conjunction with clinical interviewing, and as an outcome measure 
and research tool (Gamer, 2004). 
Gamer (2004) details three Eating Disorder Risk scales: Drive for Thinness, 
which measures terror of weight gain and yearning for thinness; Bulimia, which measures 
rumination and behaviors relating to binge eating; and Body Dissatisfaction, which 
examines displeasure with shape and body mass. Gamer (2004) also details eight 
psychological scales: Low Self-Esteem, which measures negative self-appraisal and 
feelings of insecurity; Personal Alienation, which assesses an impoverished self-
understanding; Interpersonal Insecurity, which measures reservation and distress in social 
circumstances; Interoceptive Deficits, which evaluates misperceptions in correctly 
identifying and reacting to emotional cues; Emotional Dysregulation, which assesses 
impulsivity, volatility, anger, and substance misuse; Perfectionism, which assesses 
personal and goal achievement; Asceticism, which evaluates self-denial and control; and 
Maturity Fears, which measures the wish to return to childhood and maintain a 
prepubertal fa<;ade (Gamer, 2004). 
Gamer (2004) reported that the EDI-3 was normed both nationally and 
internationally for Anorexia Restricting, Anorexia Binge/Purge, Bulimia, and Eating 
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Disorder not Otherwise Specified, as well as for adult and adolescent clinical populations. 
Additionally, Podar and Alik (2009) assessed 301 participants differing on sex, age, 
diagnosis, language and ethnicity, and examined the factorial structure of the EDI 
subscales. They found almost indistinguishable structures across clinical and non-clinical, 
as well as Western and non-Western participants, indicating that the EDI-3 is 
generalizable across cultures. 
Gamer (2004) reported that the internal consistency coefficients ranged from the 
.80s to the .90s for the three Eating Disorder Risk scales and eight psychological scales, 
across the three normative groups and four diagnostic categories. Additionally, they 
reported the median test-retest coefficients for the Eating Disorder Risk scale as .95 and 
the Psychological scales as .93 . Finally, they reported that validity was established 
through the use of factor analysis and intercorrelational studies with external eating 
disorder measures (e.g., the EAT-26 and BULIT-R) and with external measures of 
personality and psychopathology (e.g., the Rosenburg Self-Esteem Scale and MCMI-II). 
The EDI-3, therefore, should be a reliable and valid measure of eating disorder symptoms 
and psychological features in this group of substance using women in residential 
treatment. 
Millon Clinical Multiaxial Inventory-III 
The MCMI-III is a 175 item self-report measure, which is designed to be 
completed in 20 to 30 minutes and can be administered in an individual or group setting. 
The MCMI-III contains 27 scales: 24 Clinical scales, which are delineated based on 
severity and according to Axis I and Axis II disorders, as well as three Modifying 
Indices, measuring disclosure, desirability, and debasement. 
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Millon et al. (2009) delineate 11 scales measuring personality patterns: Schizoid, 
which measures detached, apathetic, and asocial characteristics; Avoidant, which 
measures caution and anxiety regarding possible social rejection; Depressive, which 
assesses chronic glumness, pessimism, and an inability to experience pleasure; 
Dependent, which measures passiveness and a need for guidance; Histrionic, which 
measures need for attention, fear of isolation, and relational manipulation; Narcisstic, 
which assesses egotism, arrogance, and willingness to engage in exploitation; Antisocial, 
which measures deception, impulsivity, and engagement in illegal activities for personal 
benefit; Sadistic, which assesses gratification from the degradation and violation of 
others; Compulsive, which evaluates perfectionism and discipline, fear of reproach, and 
antipathy towards others; Negativistic, which measures passive aggressiveness; and 
Masochistic, which assesses fostering of self-exploitation and self-debasement. 
Furthermore, Millon et al. (2009) delineate three scales which measure severe 
personality pathology, which were devised to encompass increased deterioration in 
personality, including social and psychotic deficits. The Schizotypal scale measures 
intentional isolation, selfishness, emotional blunting, and emotional guardedness. The 
Borderline scale assesses emotional lability, uncertain self-image, and paradoxical 
interpersonal relationships. The Paranoid scale assesses pervasive suspicion and mistrust 
of others, recalcitrance, and inflexibility. 
Millon et al. (2009) outline seven scales which measure moderately severe 
clinical syndromes: Anxious, which measures many forms of anxiety (e.g., specific 
phobias, somatic complaints, hypervigilance); Somatoform, which measures the 
expression of psychological complaints through body complaints; Bipolar: Manic, which 
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assesses manic symptomatology (e.g., agitation, impulsivity, and restlessness); 
Dysthymia, which evaluates apathy, chronic fatigue, social withdrawal, and anhedonia; 
Post-Traumatic Stress, which captures reaction to trauma and anxious arousal; Alcohol 
Dependence, which measures issues with alcoholism, recovery failures, and social 
consequences; and Drug Dependence, which assesses a recurrent or recent history of drug 
abuse, as well as impulsivity, and social and personal consequences. 
Finally, Millon et al. (2009) outline three scales which measure severe clinical 
syndromes. The Thought Disorder scale assesses disoriented, schizophrenic-like 
symptoms, such as hallucinations, delusions, disorganized thought and emotional 
blunting. The Major Depressive scale measures severely depressed, hopeless, and 
suicidal behaviors and cognitions. Finally, the Delusional Disorder scale examines 
antagonistic and paranoid delusions, along with disturbed thinking. 
Millon et al. (2009) noted that the MCMI-III underwent a three-step validation 
process, including 1) theoretical-substantive, 2) internal structure, and 3) external-
criterion. The validation process was sequential, with items having to meet the criteria for 
each step before they could be evaluated in the next step. The revision process utilized 
several hundred clinicians who previously utilized the MCMI-II, across 26 states and 
Canada, for a total sample of 998 subjects. These subjects included individuals from 
inpatient and outpatient treatment centers, correctional facility inmates, and college 
student counselees. 
Millon et al. (2009) reported that across the Clinical Personality Patterns, Severe 
Personality Pathology, Clinical Syndromes, and Severe Clinical Syndromes scales, 
internal consistency alpha levels ranged from .66 (Compulsive scale) to .90 (Major 
Depression), with scores exceeding .80 for 19 ofthe 24 scales. Additionally, test-retest 
reliability was established through re-administration of the MCMI-III to 87 individuals, 
over 5-14 days. Stability coefficients range from .84 to .96 for these 24 scales. Finally, 
the MCMI-III was correlated with a number of external measures, including the Beck 
Depression Inventory, Symptom Checklist-90-Revised, MMPI-2, and Michigan 
Alcoholism Screening Test. 
Personality Assessment Inventory 
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The PAl (Morey, 2007) is a 344 item, self-report inventory which measures adult 
psychopathology and personality. Morey (2007) describes 11 clinical scales, five 
treatment scales, 2 interpersonal scales and 4 validity scales, which together comprise the 
22 scales of the inventory. For the purposes of this study, only the clinical scales and one 
treatment scale will be utilized. Results are reported as t-scores, with scores above 70 
falling in the clinical range. 
Morey (2007) delineates 11 clinical scales: Somatic Complaints, which measures 
a preoccupation with physical complaints; Anxiety, which measures cognitive, 
physiological, and affective symptoms of anxiety; Anxiety-Related Disorders, which 
assesses anxiety related to phobias, traumatic stress, and obsessive compulsive disorder; 
Depression, which evaluates cognitions, emotions, and physiological symptoms 
associated with depression; Mania, which measures irritability, grandiosity, and activity 
level; Paranoia, which measures persecution, resentment, and hyper-vigilance; 
Schizophrenia, which evaluates psychotic experiences, social detachment, and thought 
disorder; Borderline, which assesses affective instability, identity problems, and self-
harm; Antisocial, which measures criminal behavior, stimulus seeking, and egocentricity; 
and Alcohol Problems and Drug Problems, which measure substance use and 
dependence, as well as problems and consequences related to use. 
Morey (2007) describes five treatment scales established to measure the 
willingness to engage in treatment as well as complicating factors related to treatment. 
For the purposes of this study, only the Suicidal Ideation scale (i.e., measuring suicidal 
ideation, plans) wasused. 
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Morey ( 1996) reported that the P AI was developed for use in both normative and 
clinical populations, in adults aged 18 years or above. The standardization sample was 
representative and modeled after the United States census. The internal consistency 
alphas were a median of .81, .82, and .86, for normative, college, and clinical 
populations. In substance using populations, median alpha levels for the full scales were 
. 78 for a methadone-using sample (Alterman et a!., 1995) and .86 for an alcoholic sample 
(Schinka, 1995). In an eating disordered sample, the mean reliability of the full scales 
was .82 (Tasca, Wood, Demidenko, & Bissada, 2002). For temporal stability, the median 
test re-test reliability was .86 in the standardization sample, with a four week interval 
between the test and retest (Morey, 1996). 
Morey (1996) accumulated data regarding convergent and discriminant validity 
correlates in order to establish the construct validity of the P AI scales. He reported 
correlations of the individual scales with more than 50 concurrent indices of 
psychopathology. Additionally, validity scales were developed to ascertain efforts 
towards impression management and strategic or careless responding. Inconsistency and 
careless responding was addressed through 1,000 computer simulations of random 
responses; 99.4% of these 'simulations' were identified by the scales. Finally, these 
validity scales were correlated with other suc:h scales on similar measures, with 
correlations ranging from .4 to .6. 
Statistical Plan 
The data obtained in the present study were analyzed using a combination of 
descriptive and inferential methods. The independent variable was dichotomous and 
measured the presence or absence of stimulant use, with the understanding that an 
absence of stimulant use still implied the presence of other types of drug use. Substance 
use was ascertained on the basis of the addictionologist's report, from the chart review. 
Due to the nature of the research, it was not possible to randomly assign participants to 
groups, nor was there a practical way to ensure equal group sizes. 
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The hypotheses for the study were analyzed using multivariate analysis of 
variance (MANOV A) and descriptive discriminant function analysis (DDA). MANOV A 
was used to determine if there were mean differences between the two substance use 
groups (i.e., stimulant use versus 'other drug' use) on the scales of the EDI-3, MCMI-III, 
and PAL Descriptive discriminant function analysis (DDA) was utilized to further assess 
the ability of each set of scales to discriminate between the two substance use groups. In 
essence, it was a multivariate follow-up to the omnibus test of significance found from 
the MANOVA. Univariate analyses were examined following the discriminant analyses; 
however, the focus ofthe analyses will be on the results ofthe MANOVA and DDA in 
order to minimize Type 1 error (Stevens, 2002). 
A number of statistical tests were used to ensure that statistical assumptions were 
met and to report the results ofMANOVA and DDA. First, multivariate normality was 
assessed by ascertaining univariate normality (e.g., removing outliers, checking 
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histograms, measures of central tendency, and standardizing skewness and kurtosis 
values). Secondly, multivariate analysis was tested using the Mahalonbis's Distance 
statistic (Meyers, Gamst, & Guarino, 2006). Homogeneity of covariance matrices was 
tested using Box's test (Field, 2009) for MANOVAs; this assumption was further 
assessed in DDA by comparing the log determinants to ensure they were in the same 
ballpark (Huberty, 2002, pp. 587-588). With regards to univariate assumptions, 
homogeneity of variance was assessed using Levene's test; violations to this test were 
followed up with FMax tests (Field, 2009). If a scale grossly violated this assumption, it 
was not be interpreted at the univariate level. Given the nature of this data, Pillai's trace 
was used as the multivariate test statistic as it is the most robust to potential issues with 
heterogeneity of variance and covariance (Meyers et al., 2006). Bonferroni corrections 
were employed for alpha levels for both multivariate (p < .017) and univariate analyses (p 
< .001) in order to guard against Type 1 error (Meyers et al., 2006). Partial eta squared 
was utilized as an effect size for the MANOVAs, eta squared was used as an effect size 
for the univariate analyses, and canonical r2 was used as an effect size for DDA (Field, 
2009). Finally, with regards to DDA, .30 was used as an interpretive cut-off for structure 
correlations (Finch, 2009; Tabachnick & Fiddell, 2001), unless there were severe 
violations in the data, in which case .50 was utilized to minimize error (Finch, 2009). 
This study employed three planned analyses based on a priori hypotheses. Using 
the EDI-3, the Drive for Thinness, Bulimia, Body Dissatisfaction, and Emotion 
Dysregulation scales were entered as dependent/outcome variables in a MANOV A and 
DDA, with the stimulant use dichotomy as the independent variable. Secondly, using the 
P AI, the stimulant use dichotomy was again the independent variable, and the 
32 
Depression, Mania, Anxiety, Schizophrenia, Borderline, and Antisocial scales were 
entered as dependent/outcome variables in a MANOV A and DDA. Finally, using the 
scales of the MCMI-111, the stimulant use dichotomy was the independent variable, and 
the Anxiety, Major Depression, Dysthymia, Bipolar: Manic, Thought Disturbance, 
Borderline, and Antisocial scales were entered as dependent/outcome variables in a 
MANOV A and DDA. Three heuristic analyses were employed to further extend the 
understanding of the relationships between the constructs. The remaining scales of each 
measure were entered as dependent variables into three MANOV As and DDAs, separated 
by measure. 
All three measures were utilized, despite overlap, as each measure contained 
unique information and scales which were not captured by other measures. Therefore, 
utilizing the scales of both measures in a single analysis may have resulted in a scale 
from one measure taking all of the variance at a multivariate level and masking the 
contribution of a similar scale on another measure. Furthermore, inclusion of both 
broadband measures permitted comparison of results on overlapping scales, thus 
speaking to validity and allowing for examination of the clinical utility of these 
instruments. 
CHAPTER III 
ANALYSES AND RESULTS 
Preliminary Analyses 
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Data were assessed for normality using measures of central tendency, histograms, 
skewness and kurtosis, and z-scores. Among the MCMI data, two participants had 
outlying scores across scales; therefore, these two participants were excluded. After this 
removal, skewness and kurtosis were calculated and standardized. The data evinced 
skewness outside the cut-off of ±3.28 (Field, 2009) in six of the 11 EDI-3 scales, three of 
the 13 PAl scales, and 12 ofthe 24 MCMI-111 scales. Kurtosis was outside the cut-off of 
±3.28 (Field, 2009) in two of the 11 EDI-3 scales, three of the 13 PAl scales, and two of 
the 24 MCMI-111 scales. Therefore, several of the scales demonstrated a non-normal 
distribution, which was expected given the clinical population. Data could not be 
transformed, however, as data evinced both positive and negative skew, platykurtic, and 
leptokurtic distributions depending on the scale; these distribution differences were likely 
due to differences in base rates of particular disorders measured by the scales. 
Mahalonobis' distance was calculated as a measure of multivariate normality (Meyers et 
al. , 2006). Ap participants fell below the critical value ofi (df 49) = 85.35,p = .001 , 
providing eviden~e for multivariate normality. Therefore, although some caution should 
be employed in interpreting these results due to violations to univariate normality, there 
was evidence supporting the assumption of multivariate normality. 
Participants were excluded from analyses due to missing data or invalid profiles; 
participant totals ranged from 110 to 114, depending on analysis. Levene's test for 
equality of variance was completed for each scale (Table 2). All scales with significant 
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results were followed up with Hartley's FMax test (Field, 2009). The critical value for the 
FMax test, given the smaller of our two group sizes (N = 31) and a = .05, was 2.63. The 
variance ratios for the following scales exceeded the critical values for the FMax test: 
Suicidal Ideation (2.84), Anxiety (6.1 0), Sadistic (2. 79), Negativistic (3.02), Masochistic 
(2.98), and Posttraumatic Stress (4.07). Although each ofthese scales violate the 
assumption of equality of variances, the Anxiety and Posttraumatic Stress scales 
demonstrated a gross violation and should not be interpreted at the univariate level. The 
remaining scales (i.e., Suicidal Ideation, Sadistic, Negativistic, Masochistic) should be 
interpreted with caution. 
Table 2 
Results from Levene's Test for Equality of Variance; All Scales 
Dependent Variable F DF 1 DF2 Sig. 
EDI-3 
Drive for Thinness 1.89 1 111 .172 
Bulimia 3.17 1 11 1 .078 
Body Dissatisfaction 0.16 1 11 1 .689 
Emotion Dysregulation 5.71 1 111 .019 
Low Self Esteem 2.51 1 112 .11 6 
Personal Alienation 8.08 1 112 .005 
Interpersonal Inseclirity 0.05 1 11 2 .829 
Interpersonal Alienation 5.52 1 112 .021 
Interoceptive Deficits 3.09 1 112 .082 
Perfectionism . 0.10 1 112 .757 
Asceticism 1.99 1 112 .1 61 
Maturit~ Fears 1.24 1 112 .269 
PAl 
Anxiety 0.01 1 111 .926 
Depression 0.79 1 111 .376 
Mania 0.50 1 111 .483 
Borderline 0.60 1 111 .441 
Antisocial 0.39 1 11 1 .536 
Somatic Concerns 4.04 1 111 .047 
Anxiety Related Disorders 0.04 1 ~ 111 .848 
Paranoia 3.27 1 111 .073 
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Table 2 (continued). 
De.eendent Variable F DF 1 DF2 Sig. 
Schizophrenia 9.83 1 111 .002 
Alcohol Concerns 0.65 1 111 .421 
Drug Concerns · 0.06 1 111 .810 
Aggression 2.39 1 111 .125 
Suicide Ideation 6.79 1 111 .010 
MCMI-111 
Anxiety 14.99 1 109 .000 
Bipolar: Manic 2.76 1 109 .099 
Dysthymia 0.92 1 109 .341 
Thought Disorder 20.43 1 109 .000 
Major Depression 0.12 1 109 .730 
Antisocial 2.90 1 109 .091 
Borderline 9.70 1 109 .002 
Schizoid 6.79 1 109 .010 
Avoidant 8.81 1 109 .004 
Depressive 0.81 1 109 .370 
Dependent 12.36 1 109 .001 
Histrionic 1.39 1 109 .241 
Narcissistic 4.02 1 109 .048 
Sadistic 19.88 1 109 .000 
Compulsive 1.353 1 109 .247 
Negativistic 38.00 1 109 .000 
Masochistic 11.05 1 109 .001 
Schizo typal 9.26 1 109 .003 
Paranoid 5.97 1 109 .016 
Somatoform 1.77 1 109 .186 
Alcohol Dependence 5.65 1 109 .019 
Drug Dependence 7.08 1 109 .009 
Posttraumatic Stress 16.85 1 109 .000 
Delusional Disorder 0.31 1 109 .582 
*Bolding denotes significance 
With regards to drug use, the sample was comprised of29.8% stimulant users, 
68.5% alcohol users, 47.6% opioid/opiate users, 28.2% GABA agonists users, 22.6% 
marijuana users, and 8.1% 'other' users. Of stimulant users, 2.7% used only stimulants, 
32.4% used stimulants and one additional substance, and 64.9% used three or more 
classes of substances. Of other drug users, 55.2% used one substance in isolation, 31.0% 
used two types of substances, and 13.8% used three or more classes of drugs. With 
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regards to eating disorders, 35.5% of the total sample was diagnosed with an eating 
disorder, according to DSM-IV criteria. With regards to comorbidities, 59.50% of 
stimulant users and 25.3% of all other types of drug users were diagnosed with a 
comorbid eating disorder. 
Results, EDI-3 
Per the a priori hypotheses, stimulant use was dichotomized as a grouping 
variable and the Drive for Thinness, Bulimia, Body Dissatisfaction, and Emotion 
Dysregulation scales were entered as dependent variables into a MANOV A. Covariance 
homogeneity was supported by Box's test, M= 15.57, F(10, 18054) = 1.48, p = .140. The 
multivariate model explained a significant portion of the variance in stimulant use, 
Pillai's Trace= 0.18 F(4, 108) = 5.83,p < .001 ,partial r/ = .18. Subsequently, univariate 
analyses were examined. Stimulant use was associated with significantly higher Emotion 
Dysregulation, F(l, 111) = 14.51,p < .001, compared to other drug use; Drive for 
Thinness, F(1, 111) = 10.42,p = .002, and Body Dissatisfaction, F(1, 111) = 3.93,p = 
.05, approached significance but did not meet the p < .001. The Bulimia scale did not 
differentiate between stimulant use and other drug use, F (1 , 111) = 2.98,p = .087. 
Means and standard deviations are presented in Table 3. 
Table 3 
A Priori Univariate Analyses, EDI-3 
Dependent Variables 
Drive for Thinness** 
Bulimia 
Body Dissatisfaction* 
Emotion 
Dysregulation * * * 
Note: *p < .05, **p < .01, ***p < .001 
Stimulant Use 
(N=33) 
40.55/14.32 
47.09/11.28 
42.45/12.93 
56.76/11.14 
Other Drug Use 
(N = 81) 
31.56/12.93 
43.63/8.63 
37.31/12.22 
49.86/7.57 
Eta Squared 
.08 
.03 
.03 
.11 
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Descriptive discriminant analysis (DDA) was used to further assess the ability of 
the four eating disorder scales to separate the two grouping variables of stimulant use and 
other drug use. Log determinants were relatively equal (Group 1: 16.85, Group 2: 17.60, 
Error: 17.21 ), providing further evidence for the homogeneity of covariance matrices. 
One function was extracted from the data, A= .82, i (df 4) = 21.32,p < .001. The 
canonical / was equal to .17, indicating that the discriminant function accounted for 
17.7% of the variance. 
Standardized canonical discriminant function coefficients (Table 4 ), which 
indicate the strength of a scale's unique contribution to a function, demonstrated that the 
function was principally predicted by Drive for Thinness, followed by the Emotion 
Dysregulation. Body Dissatisfaction negatively predicted the function. The structure 
correlations (Table 4) indicated that Emotion Dysregulation demonstrated the highest 
correlation with the function, followed by Drive for Thinness; Body Dissatisfaction and 
Bulimia were also correlated to the function, albeit at lower levels. Group centroids, the 
standardized means of the two grouping variables, were .72 for stimulant users and -.30 
for other drug users. Therefore, stimulant users were characterized by a desire for 
thinness in conjunction with dysregulated emotions. 
Table 4 
A Priori Discriminant Analysis Results, EDI-3 
Dependent Variables 
Drive for Thinness 
Bulimia 
Body Dissatisfaction 
Emotion Dysregulation 
Structure Matrix 
(Correlations) 
.66 
.35 
.41 
.78 
Standardized Discriminant 
Function Coefficients 
1.04 
-0.20 
-0.48 
0.74 
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Per the heuristic hypotheses, stimulant use was dichotomized as a grouping 
variable, and the remaining scales of the EDI-3 (e.g., Low Self-Esteem, Interoceptive 
Alienation) were entered as dependent variables into a MANOV A. Stimulant use did not 
account for a significant portion of the variance in the multivariate model, Pillai 's Trace 
= 0.1 0, F (8, 1 05) = 1.40, p = .207. Due to this lack of significance, univariate analyses 
and discriminant analysis will not be further discussed for this model. 
Results, P AI 
In accordance with a priori hypotheses, the stimulant use dichotomy was entered 
as the independent variable and the Anxiety, Depression, Mania, Schizophrenia, 
Borderline, and Antisocial scales of the P AI were entered as dependent variables into a 
MANOV A. Covariance homogeneity was supported by Box's test, M= 25.338, F(21, 
12470) = 1.11, p = .327. The multivariate model explained a significant portion of the 
variance in stimulant use, Pillai 's Trace = 0.25, F (6, 106) = 5.75, p < .OOl,partial r/ = 
.25. Univariate analyses indicated that stimulant use was associated with significantly 
higher scores on Borderline, F ( 1, 111) = 23.51, p < . 001, and Antisocial scales, F ( 1, 
111) = 21.65,p < .001, compared to other drug use. Depression, F (1, Ill)= 6.03,p = 
.016, Mania, F (l , 111) = 7.54, p = .007, and Schizophrenia, F (l, 111) = 6.85, p = .010 
approached significance but did not meet the p < .001 level. The Anxiety scale did not 
differentiate between stimulant use and other drug use, F (l, 111) = 2.15, p = .146. 
Means, standard deviations, and effect sizes are presented in Table 5. 
Table 5 
A Priori Univariate Analyses, P AI 
Dependent Variables 
Anxiety 
Depression* 
Mania** 
Schizophrenia** 
Borderline*** 
Antisocial*** 
Note: *p < .05, **p < .01, ***p < .001 
Stimulant Use 
(N=31) 
66.84114.10 
71.81/15.28 
54.35/10.71 
59.65/16.35 
75.06/13.59 
67.55/13.07 
Other Drug Use 
(N = 82) 
62.51 /13.96 
64.61/13.35 
48.73/9.32 
52.68/10.92 
62.21/12.14 
54.84/12.91 
DDA was used to determine the ability of the six personality and 
Eta Squared 
.02 
.05 
.06 
.06 
.18 
.16 
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psychopathology scales to separate stimulant use from other drug use. Log determinants 
were relatively equal (Group 1: 26.09, Group 2: 26.63, Error: 26.47), providing further 
evidence for the homogeneity of covariance matrices. One function was extracted from 
the data, A = .76, :iCdf6) = 30.42, p < .001. The canonical r 2 was equal to .24, 
indicating that the discriminant function accounted for 24.5% of the variance. 
Standardized canonical discriminant function coefficients (Table 6) indicated that the 
function was principally positively predicted by the Borderline scale, and to a much 
lesser extent, the Antisocial and Depression scales. Anxiety strongly negatively predicted 
the function; to a lesser extent, Schizophrenia also negatively predicted the function. 
The structure correlations (Table 6) demonstrated that Borderline and Antisocial evinced 
the highest correlations with the function, followed by Mania, Schizophrenia, and 
Depression. Group centroids were .92 for stimulant users and -.35 for other drug users. 
Therefore, the function characterizes stimulant users as elevated on personality disorders 
whose primary traits include impulsivity, irritability, and affective instability, and to a 
lesser extent, mood disturbance distinguished stimulant users from other drug users. The 
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role of the Schizophrenia scale is somewhat unclear, as it evinces a moderate correlation 
with the function but demonstrates a small but negative impact. 
Table 6 
A Priori Discriminant Analysis Results, P AI 
Dependent Variables 
Anxiety 
Depression 
Mania 
Schizophrenia 
Borderline 
Antisocial 
Structure Matrix 
(Correlations) 
.24 
.41 
.46 
.44 
.81 
.77 
Standardized Discriminant 
Function Coefficients 
-0.72 
0.30 
0.20 
-0.24 
1.04 
0.30 
With regards to the heuristic hypotheses, the stimulant use dichotomy was again 
entered as the independent variable, with the remaining seven scales ofthe PAl entered 
as dependent variables into a MANOV A. Covariance homogeneity was supported by 
Box's test, M = 36.11, F(28, 11929) = 1.17, p = .245. Stimulant use explained a 
significant portion of the variance in the multivariate model, Pillai 's Trace = .1 6, F(7, 
1 05) = 2.90, p = .008, partial r/ = .16. Univariate analyses indicated that stimulant use 
was associated with significantly higher scores on Paranoid, F(l , 111) = 10. 76, p = .001 , 
and Suicide Ideation scales, F(l, 111) = 11.52,p < .001, compared to other drug use. 
Drug Problems, F(1, 111) = 5.08,p = .026, and Aggression, F(1, 111) = 10.10,p = .002, 
approached significance but did not meet the p < .001 level. The Anxiety Related 
Disorders scale, F(l , 111) = 2.27,p = .135, and the Somatization scale, F(l , 111) = 1.62, 
p = .205, did not differentiate between stimulant use and other drug use. Means, standard 
deviations, and effect sizes are presented in Table 7. 
Table 7 
Heuristic Univariate Analyses, P AI 
Dependent Variables 
Somatic Concerns 
Anxiety Related Disorders 
Paranoia*** 
Alcohol Concerns 
Drug Concerns* 
Aggression** 
Suicide Ideation*** 
Note: •p < .05, .. p < .01 , ... P < .001 
Stimulant Use 
(N=31) 
Mean/SD 
59.97/13.82 
65.19/13.73 
60.68/14.71 
81.10/21.50 
83.61/23.41 
55.32/13.31 
62.26/17.81 
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Other Drug Use (N = Eta Squared 
82) 
Mean/SD 
56.71 /11.45 .01 
60.98/13.11 .02 
52.32/10.96 .09 
78.50/22.82 .00 
72.56/23.19 .04 
47.41111.27 .08 
52.51/11.69 .09 
DDA was used to further separate the stimulant group from the other drug use, 
using the six remaining P AI scales. Log determinants were approximately equal (Group 
1: 35 .92, Group 2: 36.96, Error: 36.53), providing additional evidence for the 
homogeneity of covariance matrices. One function was extracted from the data, A = .84, 
iCdf7) = 19.01, p = .008. The canonical r2 was equal to .16, indicating that the 
discriminant function accounted for 16.2% of the variance. Standardized canonical 
discriminant function coefficients (Table 8) indicated that the function was primarily and 
equally predicted by the Suicide Ideation and Paranoid scales, and to a lesser extent, the 
Drug and Aggression scales. Anxiety Related Disorders slightly negatively impacted the 
function. The structure correlations (Table 8) demonstrated that Suicide Ideation, 
Paranoia, and Aggression had the highest correlations with the function, followed by 
Drug Use. Group centroids were .71 for stimulant users and -.27 for other drug users. 
Stimulant users are thus characterized primarily in terms of their suicidality, paranoia, 
and aggression, but may also be distinguished by drug use. 
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Table 8 
Heuristic Discriminant Analysis Results, P AI 
Dependent Variables Structure Matrix 
(Correlations) 
Standardized Discriminant 
Function Coefficients 
Somatic Concerns 
Anxiety Related Disorders 
Paranoia 
Alcohol Concerns 
Drug Concerns 
Aggression 
Suicide Ideation 
.28 
.33 
.71 
.12 
.49 
.69 
.73 
Results, MCMI-III 
-0.05 
-0.22 
0.49 
0.12 
0.27 
0.28 
0.55 
Per the a priori hypotheses, the stimulant use dichotomy was entered as the 
independent variable, and the Anxiety, Bipolar: Manic, Dysthymia, Thought Disorder, 
Major Depression, Borderline, and Antisocial scales of the MCMI-III were entered as 
dependent variables into a MANOV A. Covariance homogeneity was not supported by 
Box's test, M= 83.52, F(28, 14152) = 2.72, p < .001; in conjunction with evidence of 
normality violations and unequal group sizes, these results should be interpreted with 
caution. The multivariate model explained a significant portion of the variance in 
stimulant use, Pillai 's Trace= 0.943, F(7, 1 03) = 3.31, p = .003, partial r/ = .18. 
Univariate analyses indicated that stimulant use was associated with significantly higher 
scores on Borderline, F(1, 1 09) = 20.62, p < .001, and Antisocial scales, F( 1, 1 09) = 
14.26,p < .001, compared to other drug use. Again, Bipolar: Manic, F(1, 109) = 9.76,p = 
.002, Dysthymia, F(1, 109) = 4.26,p = .041, and Thought Disorder, F(1, 109) = 8.09,p 
= .005, approached significance. The Anxiety scale was not interpreted due to violations 
in equality of variance. The Major Depression scale did not differentiate between 
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stimulant use and other drug use, F(l, 109) = 2.21 , p = .140. Means, standard deviations, 
and effect sizes are presented in Table 9 . . 
Table 9 
A Priori Univariate Analy~es, MCMI-111 
Dependent Variables Stimulant Use 
(N=33) 
Mean/SD 
Other Drug Use 
(N = 78) 
Mean/SD 
Eta Squared 
Anxiety 
Bipolar: Manic** 
Dysthymia* 
Thought Disorder** 
Major Depression 
Antisocial*** 
Borderline*** 
Note: *p < .05, **p < .01 , ***p < .001 
83.12/12.40 
67.09/22.76 
73.67/23.32 
66.03/12.71 
64.88/33.06 
79.91/15.65 
77.45/15.96 
71.15/29.31 
50.76/26.12 
62.40/27.43 
52.90/25.15 
54.60/33.38 
63.95/22.01 
56.41124.48 
DDA was used to determine the ability of the seven personality and 
.04 
.08 
.03 
.07 
.02 
.12 
.16 
psychopathology scales to separate stimulant use from other drug use. Log determinants 
showed some variability but were not grossly different (Group 1: 41.53, Group 2: 36.68, 
Error: 40.87), providing some evidence for the homogeneity of covariance matrices; 
however, caution should still be employed. One function was extracted from the data, A 
= .82, i (df7) = 21.39,p = .003. The canonical r 2 was equal to .18, indicating that the 
discriminant function accounted for 18% of the variance. Standardized canonical 
discriminant function coefficients (Table 1 0) indicated that the function was almost 
entirely driven by the Borderline scale; the Major Depression scale negatively predicted 
the function. The structure correlations (Table 1 0) demonstrated that Borderline and 
Antisocial evinced the highest correlations with the function, followed by the Bipolar: 
Manic and Thought Disturbance scale. Given the violations found with this model, 
structure correlations were not interpreted below .5, in order to minimize error 
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(Dalgleish, 1994; Finch, 2009). Group centroids were .72 for stimulant users and -.31 for 
other drug users. With the exception of the contribution ofthe Major Depression scale, 
the results of the DDA using the MCMI-III scales were entirely consistent with the 
results ofthe DDA using the PAl scales above. Therefore, despite violations the function 
again distinguishes stimulant users as elevated on personality disorders whose criteria 
include impulsivity, irritability, and affective instability; to a lesser extent, mania, thought 
disorganization, and confusion distinguished stimulant users from other drug users. 
Table 10 
A Priori Discriminant Analysis Results, MCM1-111 
Dependent Variables 
Anxiety 
Bipolar: Manic 
Dysthymia 
Thought Disorder 
Major Depression 
Antisocial 
Borderline 
Structure Matrix 
(Correlations) 
.46 
.63 
.42 
.58 
.30 
.76 
.92 
Standardized Discriminant 
Function Coefficients 
-0.07 
0.08 
0.02 
0.18 
-0.36 
0.29 
0.82 
With regards to the final heuristic hypothesis, the stimulant use dichotomy was 
entered as the independent variable, with the remaining 17 scales of the P AI entered as 
dependent variables into a MANOV A. It should be noted that this MANOV A is 
underpowered and corresponding discriminant analysis results may not be stable due to 
small sample size. Covariance homogeneity was supported by Box's test, M = 231 .57, 
F(153, 10000) = 1.57, p = .091. Stimulant use explained a significant portion ofthe 
variance in the multivariate model, Pillai 's Trace= .317, F(17, 92) = 2.52,p = .003, 
partialrt2 = .32. Univariate analyses indicated that stimulant use was associated with 
significantly higher scores on Sadistic, Negativistic, and Drug Dependence, compared to 
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other drug users. Conversely, other drug users score significantly higher on the 
Compulsivity scale, relative to stimulant users. Means, standard deviations, F-values, and 
effect sizes are presented in Table 11. 
Table 11 
Unplanned Univariate Analyses, MCMI-111 
Dependent Variables 
Schizoid 
Avoidant 
Depressive 
Dependent 
Histrionic 
Narcissistic 
Sadistic*** 
Compulsive*** 
Negativistic*** 
Masochistic* 
Schizo typal* 
Paranoid* 
Somatoform 
Alcohol Dependence* 
Drug Dependence*** 
Posttraumatic 
Stress** 
Delusional Disorder* 
Stimulant Use 
(N=30) 
Mean/SD 
54.47/22.04 
59.60/26.67 
67.33/26.45 
78.70/19.03 
49.20/27.51 
54.27/23.64 
65.30/ 12.31 
27.50/ 16.99 
67.33/15.02 
71.87/ 17.85 
55.37/22.54 
53.40/24.57 
50.80/24.42 
86.33/ 15.55 
84.30/20.18 
66.20/11 .66 
42.03/24.44 
Note: •p < .05, ••p < .01, u•p < .001 ; df are I &108 
Other Drug Use 
(N = 80) 
Mean/SD 
45.60/27.76 
52.73/31.78 
62.23/27.11 
69.04/26.59 
49.71/23.00 
49.65/ 19.30 
52.63/ 19.32 
50.53/20.80 
47.98/24.89 
58.95/28.77 
44.25/27.26 
39.75/27.35 
46.63/25.78 
75.16/27.85 
63.41/30.24 
52.49/25.96 
28.84/26.34 
Bolding denotes an inability to interpret due to violations to equality of variance 
F 
2.47 
1.11 
0.79 
3.32 
0.01 
1.10 
11.17 
29.35 
15.92 
5.27 
3.97 
5.73 
0.59 
4.62 
12.23 
7.75 
5.69 
Eta 
Squared 
.02 
.01 
.01 
.03 
.00 
.01 
.09 
.21 
.13 
.05 
.04 
.05 
.01 
.04 
.10 
.07 
.05 
DDA was used to further separate the stimulant group from other drug use using 
the 17 remaining PAI scales. Log determinants were not equal (Group 1: 96.91, Group 2: 
87.65, Error: 96.56), providing evidence against the homogeneity of covariance matrices. 
One function was extracted from the data, A = .68, i (df 17) = 37.99,p = .002. The 
canonical r2 was equal to .32, indicating that the discriminant function accounted for 32% 
of the variance. 
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Due to violations in assumptions, .50 was used as an interpretive cut-off to 
minimize error (Dalgleish, 1994). Standardized canonical discriminant function 
coefficients (Table 12) indicated that the function was primarily predicted by the 
Histrionic, Negativistic, Avoidant, and Posttraumatic Stress scales. The Compulsive scale 
was a negative predictor of the function. The structure correlations (Table 12) 
demonstrated that the function was primarily positively correlated with Negativistic scale 
and negatively correlated with the Compulsive scale. There was some disagreement 
between the standardized coefficients and the structure correlations (e.g., Histrionic 
scale). Therefore, the structure correlations will be the focus of interpretation, as there is 
some evidence that these correlations evince increased stability in small sample sizes 
(Stevens, 2002). Group centroids were 1.10 for stimulant users and -.41 for other drug 
users. Therefore, the function characterizes stimulant users in terms of their passive-
aggression and lack of compulsivity. 
Table 12 
Heuristic Discriminant Analysis Results, MCM1-111 
Dependent Variables 
Schizoid 
Avoidant 
Depressive 
Dependent 
Histrionic 
Narcissistic 
Sadistic 
Compulsive 
Negativistic 
Masochistic 
Schizo typal 
Paranoid 
Somatoform 
Structure Matrix 
(Correlations) 
.22 
.15 
.13 
.26 
-.01 
.15 
.47 
-.77 
.56 
.32 
.28 
.33 
.11 
Standardized Discriminant 
Function Coefficients 
0.35 
0.54 
-0.76 
-0.07 
0.62 
-0.00 
-0.21 
-0.83 
0.55 
0.13 
-0.11 
-0.15 
-0.33 
Table 12 (continued). 
Dependent Variables 
Alcohol Dependence 
Drug Dependence 
Posttraumatic Stress 
Delusional Disorder 
Structure Matrix 
(Correlations) 
.30 
.49 
.39 
.34 
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Standardized Discriminant 
Function Coefficients 
-0.04 
-0.05 
0.52 
0.09 
CHAPTER IV 
SUMMARY 
Discussion 
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Consistent with previous literature, women who used stimulants were separated 
from women who used all other forms of drugs on the basis of a relatively cohesive 
pattern of symptomatology. First and foremost, scales measuring traits linked with 
borderline personality disorder consistently and overwhelming separated stimulant users 
from other drug users. Additionally, scales measuring features of antisocial personality 
disorder consistently discriminated between stimulant users and other drug users, though 
these scales demonstrated less of an impact. These results are consistent with overlap 
between the diagnostic criteria of these two disorders, as they both feature difficulties 
with impulsivity, aggression, and emotion regulation (APA, 2000). Results are also 
consistent with findings of neuroimaging studies, which suggest that individuals addicted 
to stimulant drugs experience impairment in cognitive inhibition, emotion regulation, and 
impulsivity (review: Li & Sinha, 2008). The temporal precedence of stimulant use and 
these symptoms are still under investigation; however endophenotypic markers in 
humans (Ersche, Williams, Robbins & Bullmore, 2013) and trait studies in animals 
(Badiani et al., 2011) suggest that impairments precede stimulant use, but are exacerbated 
upon initiation of drug use. 
Secondary to these personality types, stimulant users appeared to be separated 
from other drug users by mood disturbance. Both the PAI and MCMI-III separated 
stimulant users on the basis of manic symptoms. It was beyond the scope of this study to 
elucidate whether women experienced true symptoms of mania, or presented with manic-
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like symptoms secondary to their stimulant use. Considering the rather paradoxical 
research investigating the use of prescription stimulants as a treatment for bipolar 
disorder (Pagano et al., 2008; Wingo & Ghaemi, 2008), it may be possible that women 
with mania were attempting to self-medicate their symptoms. It is equally possible that 
the measures utilized in the study had difficulty differentiating between the two 
presentations, given the overlap in symptoms. When using the MCMI-III, the average 
individual using stimulants reached the clinical range on the Bipolar: Manic scale; 
however, on the P AI, the average stimulant user was in the normative range on the Mania 
scale. Therefore, it may be that the PAl demonstrated better clinical utility in separating 
true symptoms of mania from those of stimulant use. 
There was some evidence that depressive symptomatology also separated 
stimulant use from other drug use, although there was some conflict between measures. 
Results from planned analyses using the P AI indicated that depression was moderately 
correlated with stimulant use and had a small impact on predicting stimulant use, whereas 
results from the MCMI-III did not. Given the numerous violations of assumptions in the 
MCMI-III data, the results ofthe PAl should be accorded more weight. Additionally, the 
inclusion of both Dysthymia and Major Depression scales into the planned analysis using 
the MCMI-III may have diluted the results at the multivariate level and masked group 
differences. Therefore, consistent with previous research, women using stimulants may 
suffer from higher rates of depression and overall mood disturbance, but these clinical 
syndromes may play less of a role than severe personality pathology. 
With regards to thought disturbance or psychosis, results suggested that stimulant 
users may experience slightly higher levels of symptomatology than other drug users. 
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However, scales measuring these constructs were correlated with functions measuring 
stimulant use, but either did not differentiate or made a small negative impact on 
functions separating stimulant use from other drug use. Thus, it may be that individuals 
experiencing thought disturbance are less likely to seek stimulants, particularly as the 
literature suggests that stimulant use may exacerbate positive symptoms of psychosis 
(reviews: reviews: Dawe et al., 2009; Shoptaw et al., 2009). Conversely, women who 
chronically use stimulants may find that they temporarily experience psychotic symptoms 
as a result of their use, but may not have insight into the relationship between stimulant 
use and psychosis. The average scores of stimulant users indicated that these women may 
experience "brief reactive psychosis" (Millon et al., 2009, p. 24) and may occasionally 
display inappropriate affect, disorganized thinking, and social isolation. 
Exploratory analyses indicated that stimulant users were separated principally by 
elevations in scales measuring symptoms of suicidal ideation, paranoia, and aggression, 
and to a lesser extent, drug use. Additionally, stimulant use was defined by a passive-
aggressive personality style, which was described as "vacillation between deference and 
defiance, between obedience and aggression," (Millon et al., p.l8). Ofthese scales, only 
aggression was below the clinical range for experiencing significant symptom related 
distress or consequences. On the surface, these may appear to be a cluster of unrelated 
symptoms. However, each of these scales measure distinct diagnostic or associated 
features of borderline personality disorder (AP A, 2000), giving additional weight to the 
premise that treatment-seeking women using stimulants may be primarily defined by 
borderline personality disorder. Specifically, these scales capture the following 
symptoms, as defined by AP A (2000): "a pattern of ... interpersonal relationships 
characterized by alternating between extremes of idealization and devaluation," 
"impulsivity," "recurrent suicidal behavior, gestures, or threats," "affective instability," 
"inappropriate, intense anger or difficulty controlling anger," "transient, stress-related 
paranoid ideation," (p. 710) and the associated feature of"psychotic-like 
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symptoms . . . during times of stress," (p. 708). Stimulant use may simultaneously 
aggravate symptoms of borderline personality disorder (e.g., impulsivity, aggression) and 
serve as a coping mechanism for mood dysregulation and affective disturbance. 
These findings are largely consistent with the results of Chen et al. (20 11 ), in that 
mood disorder, psychotic symptoms, borderline personality disorder, and antisocial 
personality disorder symptoms are highly problematic among women who use stimulant 
drugs. Furthermore, results are consistent with Feske et al. (2006), who reported that 
borderline personality disorder was a significant predictor for multiple categories of 
substance use, including poly-substance use. Within our sample, 97.3% of women using 
stimulants also used at least one other substance, compared to 44.8% of women using 
other types of substances. 
Consistent with previous research, our sample of women presenting with 
stimulant use was saturated with comorbid eating disorder diagnoses (59.5%), compared 
to women presenting with other substance use disorders (25.3%). With regard to eating 
disordered symptomatology, women who used stimulants were separated from other drug 
users primarily by Emotion Dysregulation, a psychological scale posited to be associated 
with eating disorders, and Drive for Thinness. Although Emotion Dysregulation had a 
marginally higher correlation with the function defining stimulant use, Drive for Thinness 
overwhelmingly predicted stimulant use. Therefore, consistent with previous research, 
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stimulant use was associated with caloric constraint, extreme dieting, and a yearning for 
thinness, above and beyond other types of drug use. Additionally, it may be that the 
extreme dieting enacted by stimulant users interacted with their mood to exacerbate 
difficulties with regulating emotions. Previous research indicates that starvation is 
associated with symptoms mimicking mood disturbance (Casper, 1998; Pearlstein, 2002). 
Given the physiological properties associated with stimulant use (e.g., decreased 
hunger, euphoria), it is possible that stimulant use served in a functional nature, in that it 
improved the individual's mood and ability to diet. Although this study was not causal in 
nature, the thin ideal espoused by women who used stimulants suggests that their 
stimulant use may have developed as a result of their motivation to lose weight, 
consistent with hypotheses in prior research (Baker, Mitchell, Neale, & Kendler, 2010; 
Holderness et al. , 1994). Further research is needed to clarify the temporal precedence of 
stimulant use in women with eating disordered symptomatology. 
Contrary to a priori hypotheses, stimulant users were not separated from other 
drug users by anxiety or anxiety related disorders. Stimulant users still appear to have 
difficulty with anxiety, as their average scores on anxiety and anxiety-related scales were 
suggestive of clinically significant symptoms. Given the link to borderline personality 
disorder, stimulant users may experience anxiety symptoms as one of numerous, intense 
mood states, thus explaining the elevations in scores. As women who used stimulants 
were also poly-substance users, they may seek different substances to alleviate particular 
mood states (e.g., stimulants for dysphoria, sedatives for anxiety). However, women 
presenting with pure anxiety disorders may seek other types of drugs, as the consistent 
heightened physiological arousal associated with anxiety may cause aversive reactions to 
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stimulants. Additionally, anxiety symptoms may partially result from stimulant use. For 
example, multiple animal studies have demonstrated elevations in anxiety in rats 
administered cocaine; studies suggested that consistent stimulant use resulted in 
anxiogenic effects (Erb, Kayyali, & Romero, 2006; Mantsch et al., 2008; Muller et al., 
2008). 
Finally, stimulant use was not separated from other drug use by purging 
behaviors, contrary to the a priori hypothesis. Given the extensive evidence in the 
literature for this relationship, the lack of findings in this study was likely related to 
limitations in instrumentation. This study did not have a pure measure of purging, but 
rather, a scale measuring the combination ofbingeing and purging, as well as associated 
features such as drug use (i.e., the Bulimia scale). Therefore, many items on the scale 
may not have been relevant to the purging construct and may have masked important 
differences in purging behaviors between stimulant users and other drug users. The 
results of this study should not be interpreted as evidence against the stimulant use and 
purging relationship, particularly as constructs associated with purging were significant 
in the stimulant use profile. 
Implications for Treatment 
Given these findings, it is important to note that women seeking treatment for 
stimulant use disorders may present with a number of serious psychological problems. In 
such women, stimulant use may be secondary to longstanding personality pathology (i.e., 
borderline personality disorder) and eating disorder symptomatology. It will be necessary 
to carefully screen clients presenting for stimulant use and to triage their psychological 
and medical problems, focusing on those which may be life threatening (e.g., suicidality, 
starvation associated with anorexia). If these features are present, the necessity for 
hospitalization should be carefully evaluated. Subsequently, a treatment plan should be 
developed, with the knowledge that an addiction focused treatment plan may not be 
effective in isolation, as it may not consider or treat the primary problems motivating 
stimulant use. 
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Given the findings of the current study, stimulant users may benefit from 
Dialectical Behavioral Therapy (DBT) in an effort to treat the symptomatology 
associated with borderline personality disorder (Linehan et al., 2006) and accompanying 
substance use (van den Bosch, Verheul, Schippers, & van den Brink, 2002); there is 
limited evidence regarding its effectiveness in treating eating disorders (e.g., Safer, 
Robinson, & Jo, 2010), although skills learned may present some benefit to women with 
eating disorders. DBT focuses on skill acquisition in the areas of distress tolerance, 
emotion regulation, interpersonal effectiveness, and mindfulness (Linehan, 1993). 
Women presenting with comorbid stimulant use and antisocial personality 
disorder may benefit from motivational enhancement therapy (Miller, Zweben, 
DiClemente, & Rychtrik, 1992), to reduce their substance use and aid in treatment 
attendance and motivation. However, if stimulant users present with primarily eating 
disorder symptomatology, cognitive behavioral approaches (e.g., cognitive behavioral 
therapy for eating disorders; Fairburn, 2008) should be considered in order to target the 
underlying desire for thinness and weight control. It is important to note that the results of 
the current study are isolated to women and these treatment implications may not be 
generalizable to men who seek treatment for stimulant use. 
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Limitations of the Current Study 
The current study had several limitations. Due to time constraints, it was not 
possible to collect more than 124 participants, so power may have been a limitation, 
particularly in the exploratory analyses which utilized a large number of scales. 
Additionally, several scales within the data demonstrated a non-normal distribution, 
which could not be corrected due to inconsistencies in the directionality of the skewness 
and kurtosis. Although multivariate tests for normality were within an acceptable range, 
the lack of equality between cell sizes, in conjunction with the lack of univariate 
normality in a number of the scales, indicate that these results should be interpreted with 
caution as the combination of these two violations can result in an overly liberal F 
statistic (Meyers et al., 2006). 
Additionally, all of the measures utilized in this study were self-reported, which 
introduced the opportunity for bias via impression management and misunderstanding. 
Attempts were made to control for bias where possible (e.g., use of validity scales, 
presence of the patient's mental health clinician). However, the study would have 
benefited from collateral sources of reporting, clinician based measures, or behavioral 
monitoring, such as ecological momentary based assessment. 
The current study may also have been hindered by uncontrolled, third variables. 
As the study examined only the presence or absence of stimulant use, women in both 
groups may have used a multitude of other drugs. This approach to the data increased 
confidence in the external validity of the results, as many individuals seeking treatment 
for alcohol and drug use present with poly-drug use, a premise which was supported by 
our data. However, this approach failed to account for the possibility that a different drug 
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may have been responsible for the group differences or masked true differences. 
Additionally, other, unmeasured constructs besides substance use may have accounted for 
the group differences in personality and psychopathology, The overlap in findings 
between the current study and the literature, however, do not provide evidence of a third 
variable problem. 
Finally, the generalizability of the results are somewhat limited in this study, 
given the lack of randomization, use of an accessible population, lack of anorexia 
nervosa, restricting subtype diagnoses, and the complete lack of male participants. As the 
entire sample is from a treatment center in the southeastern United States, the sample 
may be unrepresentative of the general population or may be heterogeneous in some way. 
Furthermore, it was beyond the resources of this study to collect a sample of pure 
stimulant users. Although the current study offers much in the way of ecological validity, 
results of stimulant users who are also poly-drug users may not generalize to pure 
stimulant users. 
Future Directions 
Future studies should investigate potential gender differences in the clinical 
presentation of individuals with stimulant use disorders, as this study used only women 
participants. Furthermore, future studies should attempt to include a full range of eating 
disorder diagnoses (e.g., ANr), as well as both pure and poly-drug stimulant users, to 
more fully tease apart differences in clinical presentation associated with various patterns 
of comorbidity. Additionally, the results of this study should be replicated in a larger 
study, as certain exploratory analyses lacked the power to adequately rule out type I and 
II error. Furthermore, although numerous studies hypothesized the causal relationship 
between stimulant use, emotion regulation, and eating disorder symptomatology, the 
literature would benefit from a well-controlled longitudinal study to examine the nature 
of these relationships. 
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